Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal
За пределами вакцин: краткий обзор арсенала против COVID-19 на основе малых молекул и пептидов
2022-09-06
SCID: 54.1/5q94xg6a
Discuss with AI
SARS-CoV-2antiviral drug targetsdrug repurposingpeptide-based therapeuticssmall molecule antivirals
Figures from the paper
Abstract (AI)
Unprecedented efforts of the researchers have been witnessed in the recent past towards the development of vaccine platforms for the control of the COVID-19 pandemic. Albeit, vaccination stands as a practical strategy to prevent SARS-CoV-2 infection, supplementing the anti-COVID19 arsenal with therapeutic options such as small molecules/peptides and antibodies is being conceived as a prudent strategy to tackle the emerging SARS-CoV-2 variants. Noteworthy to mention that collective efforts from numerous teams have led to the generation of a voluminous library composed of chemically and mechanistically diverse small molecules as anti-COVID19 scaffolds. This review article presents an overview of medicinal chemistry campaigns and drug repurposing programs that culminated in the identification of a plethora of small molecule-based anti-COVID19 drugs mediating their antiviral effects through inhibition of proteases, S protein, RdRp, ACE2, TMPRSS2, cathepsin and other targets. In light of the evidence ascertaining the potential of small molecule drugs to approach conserved proteins required for the viral replication of all coronaviruses, accelerated FDA approvals are anticipated for small molecules for the treatment of COVID19 shortly. Though the recent attempts invested in this direction in pursuit of enrichment of the anti-COVID-19 armoury (chemical tools) are praiseworthy, some strategies need to be implemented to extract conclusive benefits of the recently reported small molecule viz. (i) detailed preclinical investigation of the generated anti-COVID19 scaffolds (ii) in-vitro profiling of the inhibitors against the emerging SARS-CoV-2 variants (iii) development of assays enabling rapid screening of the libraries of anti-COVID19 scaffold (iv) leveraging the applications of machine learning based predictive models to expedite the anti-COVID19 drug discovery campaign (v) design of antibody-drug conjugates.
Key Findings
1
Medicinal chemistry and drug-repurposing efforts have generated chemically and mechanistically diverse small-molecule anti-COVID-19 candidates.
2
Reported compounds target proteases, spike protein, RdRp, ACE2, TMPRSS2, cathepsins, and other host or viral factors.
3
Small molecules may be able to target conserved coronavirus replication proteins, supporting their potential for broad antiviral activity and accelerated COVID-19 treatment approvals.
4
Small molecules, peptides, and antibodies are presented as complementary therapeutic options to vaccination for addressing emerging SARS-CoV-2 variants.
5
The review recommends detailed preclinical testing, variant-focused in-vitro profiling, rapid screening assays, machine-learning prediction, and antibody-drug conjugate development.
Research Object
small molecule- and peptide-based anti-COVID-19 therapeutic agents targeting SARS-CoV-2
Research Subject
the medicinal chemistry, antiviral mechanisms, and development strategies of small molecule- and peptide-based anti-COVID-19 agents
Publication Details
Publication Date
2022-09-06
Journal
Publisher
ISSN
Cited by
36
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
A pneumonia outbreak associated with a new coronavirus of probable bat origin2020
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects2020
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease2020
Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor2016